<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000662449"><TermName>ADE regimen</TermName><TermPronunciation>(… REH-jih-men)</TermPronunciation><TermDefinition><DefinitionText>An abbreviation for a chemotherapy combination used  to treat childhood acute myeloid leukemia (AML). It includes the drugs cytarabine (Ara-C), daunorubicin hydrochloride, and etoposide phosphate. Also called ADE.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000725909" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;ADE regimen&quot;" language="en" id="_3"/><MediaLink ref="CDR0000725908" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;régimen ADE&quot;" language="es" id="_4"/><SpanishTermName>régimen ADE</SpanishTermName><SpanishTermDefinition><DefinitionText>Abreviatura del nombre de  un régimen de quimioterapia combinada que se usa para tratar la leucemia mieloide aguda (LMA) infantil. Incluye los medicamentos citarabina (Ara-C), clorhidrato de daunorrubicina y fosfato de etopósido. También se llama ADE.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2010-04-23</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000681926">ADE</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
